Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

969 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Results of a Phase 3 Randomized Prospective Trial of Erectile Tissue-Sparing Intensity-Modulated Radiation Therapy for Men With Clinically Localized Prostate Cancer.
Zhang E, Ruth KJ, Buyyounouski MK, Price RA Jr, Uzzo RG, Sobczak ML, Pollack A, Wong JK, Chen DYT, Hallman MA, Greenberg RE, Watkins-Bruner D, Al-Saleem T, Horwitz EM. Zhang E, et al. Among authors: pollack a. Int J Radiat Oncol Biol Phys. 2023 Apr 1;115(5):1074-1084. doi: 10.1016/j.ijrobp.2022.12.008. Epub 2022 Dec 23. Int J Radiat Oncol Biol Phys. 2023. PMID: 36566906 Free PMC article. Clinical Trial.
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials.
Nguyen PL, Huang HR, Spratt DE, Davicioni E, Sandler HM, Shipley WU, Efstathiou JA, Simko JP, Pollack A, Dicker AP, Roach M, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Rabinovitch RA, Peters CA, Rodgers JP, Tran P, Feng FY. Nguyen PL, et al. Among authors: pollack a. Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):521-529. doi: 10.1016/j.ijrobp.2022.12.035. Epub 2022 Dec 31. Int J Radiat Oncol Biol Phys. 2023. PMID: 36596347 Free PMC article.
Integrated framework for quantitative T2-weighted MRI analysis following prostate cancer radiotherapy.
Zacharaki EI, Breto AL, Algohary A, Wallaengen V, Gaston SM, Punnen S, Castillo P, Pattany PM, Kryvenko ON, Spieler B, Ford JC, Abramowitz MC, Dal Pra A, Pollack A, Stoyanova R. Zacharaki EI, et al. Among authors: pollack a. Phys Imaging Radiat Oncol. 2024 Oct 24;32:100660. doi: 10.1016/j.phro.2024.100660. eCollection 2024 Oct. Phys Imaging Radiat Oncol. 2024. PMID: 39563782 Free PMC article.
A Smart Water Bottle and Companion App (HidrateSpark 3) to Improve Bladder-Filling Compliance in Patients With Prostate Cancer Receiving Radiotherapy: Nonrandomized Trial of Feasibility and Acceptability.
Jin W, Montoya C, Rich BJ, Taswell CS, Noy M, Kwon D, Spieler B, Mahal B, Abramowitz M, Yechieli R, Pollack A, Dal Pra A. Jin W, et al. Among authors: pollack a. JMIR Cancer. 2024 Sep 10;10:e51061. doi: 10.2196/51061. JMIR Cancer. 2024. PMID: 39255484 Free PMC article. Clinical Trial.
HRS Improves Active Surveillance for Prostate Cancer by Timely Identification of Progression.
Kimbel IM, Wallaengen V, Zacharaki EI, Breto AL, Algohary A, Carbohn S, Gaston SM, Soodana-Prakash N, Freitas PFS, Kryvenko ON, Castillo P, Abramowitz MC, Ritch CR, Nahar B, Gonzalgo ML, Parekh DJ, Pollack A, Punnen S, Stoyanova R. Kimbel IM, et al. Among authors: pollack a. Acad Radiol. 2024 Dec 17:S1076-6332(24)00853-5. doi: 10.1016/j.acra.2024.11.008. Online ahead of print. Acad Radiol. 2024. PMID: 39694787
Evaluating 4Kscore's role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS score.
Hougen HY, Reis IM, Han S, Prakash NS, Thomas J, Stoyanova R, Castillo RP, Kryvenko ON, Ritch CR, Nahar B, Gonzalgo ML, Gaston SM, Abramowitz MC, Dal Pra A, Mahal BA, Pollack A, Parekh DJ, Punnen S. Hougen HY, et al. Among authors: pollack a. Prostate Cancer Prostatic Dis. 2024 Sep 27. doi: 10.1038/s41391-024-00898-w. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39333697
Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials.
Patel KR, Nguyen PL, Proudfoot JA, Liu Y, Pra AD, Spratt DE, Pollack A, Sandler HM, Efstathiou JA, Lawton C, Simko JP, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, Hall WA, Desai AB, Pugh SL, Davicioni E, Tran PT, Feng FY. Patel KR, et al. Among authors: pollack a. Eur Urol Oncol. 2024 Nov 13:S2588-9311(24)00246-3. doi: 10.1016/j.euo.2024.10.017. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39542826
Assessing the Molecular Heterogeneity of Prostate Cancer Biopsy Sampling: Insights from the MAST Trial.
Ajami T, Yu H, Porto JG, Prakash NS, Williams A, Avda Y, Malpani A, Mendiola DF, Freitas PFS, Khandekar A, Swain S, Gaston S, Mahal B, Cortizas E, Szczotka Z, Gerard T, Kava B, Stoyanova R, Kryvenko ON, Castillo P, Ritch CR, Nahar B, Gonzalgo ML, Pollack A, Parekh DJ, Punnen S. Ajami T, et al. Among authors: pollack a. Eur Urol Focus. 2024 Dec 10:S2405-4569(24)00256-6. doi: 10.1016/j.euf.2024.11.012. Online ahead of print. Eur Urol Focus. 2024. PMID: 39665894
969 results